Pregnancy, Childbirth, and HIV

The Latest

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

By Barbara Jungwirth and Myles Helfand

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand

Debate Over Dolutegravir in Early Pregnancy: A Top HIV Clinical Development of 2018

In 2018, the same year we learned that a two-drug initial HIV treatment regimen featuring dolutegravir (Tivicay, DTG) was viable for many of our patients, we also got a much-less-welcome dolutegravir (Tivicay, DTG)-related surprise. Early in the year...

By David Alain Wohl, M.D.

This Week in HIV Research: This Is Your Brain on Stigma

The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Transgender Women in the Spotlight

Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?

By Barbara Jungwirth and Myles Helfand

Why U=U Does Not Cover Breastfeeding

"Undetectable equal untransmittable" is sometimes wrongly interpreted as covering all ways that HIV can be transmitted.

By Simon Collins for HIV i-Base

PrEP Is Safe for Pregnant Women Who Want the HIV Prevention Drug, a New Study Finds

Pre-exposure prophylaxis (PrEP) is safe for pregnant women to use, according to new research presented at the HIV Research for Prevention (HIVR4P2018) conference in Madrid, Spain.

By Sony Salzman